Isoxsuprine Drip Dose and Preparation for Tocolysis
I cannot recommend isoxsuprine for tocolysis as the FDA-approved labeling only provides dosing for oral administration (10-20 mg three or four times daily), with no approved intravenous formulation or dosing guidance 1. The available evidence does not support the use of intravenous isoxsuprine as a standard tocolytic agent, and the FDA labeling explicitly contraindicates its use immediately postpartum or in the presence of arterial bleeding 1.
Critical Safety Concerns
The limited research available reveals significant maternal risks:
- Pulmonary edema has been documented when isoxsuprine was combined with dexamethasone, particularly with positive fluid balance (+5.2 liters over 48 hours) 2
- Maternal tachycardia and vomiting occur in approximately 8% of cases 3
- The drug requires careful fluid management and continuous monitoring
Historical Context from Available Research
One prospective study used the following regimen (though this is NOT FDA-approved):
- IV infusion: 40 mg isoxsuprine until uterine quiescence
- IM maintenance: 10 mg every 4 hours for first 24 hours
- Oral maintenance: 40 mg sustained-release capsules twice daily until delivery or 37 weeks 3
An older study referenced infusion rates of 150-200 mcg/minute (0.15-0.2 mg/minute), with total doses reaching 560 mg over 48 hours 4, 2.
Clinical Reality
Isoxsuprine has been largely abandoned in modern obstetric practice due to lack of FDA approval for IV tocolysis, significant maternal side effects (particularly cardiovascular complications and pulmonary edema), and availability of safer alternatives with better evidence bases. The drug is only FDA-approved for oral use in peripheral vascular disease, not for tocolysis 1.
Recommended Alternatives
Consider evidence-based tocolytics with established safety profiles:
- Nifedipine (calcium channel blocker)
- Indomethacin (for short-term use <32 weeks)
- Terbutaline (subcutaneous for acute situations) 5
If isoxsuprine is being considered due to local practice patterns or resource limitations, this requires immediate consultation with maternal-fetal medicine specialists and institutional review, as you would be using the medication off-label without FDA guidance for IV preparation or administration.